Audit 368645

FY End
2024-12-31
Total Expended
$15.28M
Findings
0
Programs
19
Organization: Vitalant (AZ)
Year: 2024 Accepted: 2025-09-29

Organization Exclusion Status:

Checking exclusion status...

Findings

No findings recorded

Programs

ALN Program Spent Major Findings
93.RD Recipient Epidemiology and Donor Evaluation Study IV - Pediatric (reds-IV-P) - Center for Transfusion Laboratory Studies (ctls) $3.30M Yes 0
93.RD Covid-19 - National Sars-Cov-2 Seroincidence Studies in Blood Donors $2.39M Yes 0
93.RD Transfusion-Transmissible Infections Monitoring System (ttims) Laboratory and Risk Factor Coordinating Center (lrcc) $1.99M Yes 0
93.RD Recipient Epidemiology and Donor Evaluation Study IV - Pediatric (reds-IV-P) Brazil Transfusion Safety Research Program $1.43M Yes 0
93.RD Recipient Epidemiology and Donor Evaluation Study IV - Pediatric (reds-IV-P) - Domestic Hub $1.27M Yes 0
93.RD Niaid Virology Quality Assurance (vqa) $496,169 Yes 0
93.839 Blood Diseases and Resources Research $467,682 Yes 0
93.RD External Quality Assurance Program Oversight Laboratory (eqapol) $257,998 Yes 0
93.RD Niaid External Quality Assurance Program Oversight Laboratory (eqapol) $228,532 Yes 0
93.RD Development, Validation & Use of Biotinylation to Measure Post-Transfusion Red Blood Cell Kinetrics in the Context of Regulatory Studies for the Approval of Novel Or Modified Blood Products in the USA $216,779 Yes 0
93.083 Prevention of Disease, Disability, and Death Through Immunization and Control of Respiratory and Related Diseases $211,463 Yes 0
93.RD Transfusion-Transmissible Infections Monitoring System (ttims) - Donation Database Coordinating Center (ddcc) $176,962 Yes 0
93.837 Cardiovascular Diseases Research $147,983 Yes 0
93.855 Allergy and Infectious Diseases Research $90,434 Yes 0
93.866 Aging Research $79,784 Yes 0
47.084 Nsf Technology, Innovation, and Partnerships $71,859 Yes 0
93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research $42,072 Yes 0
93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders $18,771 Yes 0
93.067 Global Aids $99 Yes 0

Contacts

Name Title Type
GKT4L2JZJ622 Steven Sweet Auditee
4157496613 Scott Enos Auditor
No contacts on file

Notes to SEFA

Basis of Accounting: The accompanying Schedule of Expenditures of Federal Awards (SEFA) includes the federal grant activity of Vitalant and Affiliates (the Company) and is presented on the accrual basis of accounting. The information in the SEFA is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance). The SEFA does not include payments received under the traditional Medicare and Medicaid reimbursement programs, as these programs are outside the scope of the Uniform Guidance. There were no donated goods and personal protective equipment received from federal sources that required recognition or disclosure in the notes to the SEFA.
The Company does not use the 10 percent de minimis indirect cost rate provided for in the Uniform Guidance.
The program titles and assistance listing numbers were obtained from the respective grant agreements. Per the Federal Audit Clearinghouse instructions, the Company should report the awarding federal agency’s two-digit prefix, followed by the three-digit assistance listing extension number. If the three-digit assistance listing extension number is unknown, then the awarding federal agency’s two-digit prefix is followed by “RD” (Research and Development), as well as including the federal contract number as an additional identifier.